Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL	acute lymphoblastic leukemia	Recruiting	Phase 2	2025-11-21		NCT05940961

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Hospital of Nantong University	71
Jining Medical University	15
Northern Jiangsu People's Hospital	51
Sheng-Li Xue, MD	2
Suzhou Hospital of Traditional Chinese Medicine	9
The First Affiliated Hospital of Bengbu Medical University	47
The Second People's Hospital of Huai'an	14

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Soochow University	Suzhou	China	101

Clinical trials